SignalXSignalX

ARVINAS, INC. (ARVN) 8-K Current Report: March 18, 2026

Filed: March 18, 2026
Health Care
Pharmaceutical Preparations
ARVINAS, INC. Overview

ARVINAS, INC. (ARVN) 8-K current report filed with SEC EDGAR on March 18, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
2 items

  • Item 7.01: Regulation FD Disclosure
  • Item 8.01: Other Events

ARVINAS, INC. 8-K Mar 18, 2026 Event Analysis

Item 7.01 · Regulation FD Disclosure

  • • Positive Phase 1 data for ARV-102 showing >50% LRRK2 degradation in cerebrospinal fluid after 28 days in Parkinson’s patients
  • • ARV-102 is an oral PROTAC designed to cross the blood-brain barrier targeting LRRK2, a key Parkinson's disease protein
  • • Data from randomized, double-blind, placebo-controlled multiple dose cohort presented at AD/PD™ 2026 conference
  • • Clinical progress validates Arvinas’ brain-penetrant PROTAC platform, enhancing pipeline and future therapeutic potential
  • • Data release may boost investor confidence and valuation based on first clinical proof of mechanism in neurodegeneration

Item 8.01 · Other Events

  • • Positive Phase 1 data for ARV-102 showing >50% LRRK2 degradation in CSF of Parkinson’s patients after 28 days treatment
  • • ARV-102 well tolerated at 20 mg, 40 mg, 80 mg doses, no serious adverse events or lung function issues observed
  • • Drug demonstrated dose-dependent brain penetration with plasma half-life of 68 hours, supporting once-daily oral dosing
  • • Biomarker reductions (CD68, GPNMB) indicate target engagement relevant to LRRK2-related neuroinflammation and disease pathology
  • • Plans to start Phase 1b trial in progressive supranuclear palsy Q2 2026 and potential registrational trial in late 2026 signal accelerated development path

Other ARVINAS, INC. 8-K Filings

8-K Feb 24, 2026

Get deeper insights on ARVINAS, INC.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.